Recent News

• 01.13.2026 - Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
• 01.13.2026 - Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
• 12.19.2025 - Lifeward Appoints Bob Marshall as Chairman of the Board
• 12.17.2025 - Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
• 12.03.2025 - Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
• 11.17.2025 - UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
• 11.14.2025 - Lifeward Ltd. Reports Third Quarter 2025 Financial Results
• 11.10.2025 - Lifeward to Report Third Quarter Financial Results on November 14, 2025

Recent Filings

• 01.13.2026 - 8-K Current report
• 01.13.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 8-K Current report
• 01.06.2026 - EFFECT Notice of Effectiveness
• 01.02.2026 - S-3/A Registration statement under Securities Act of 1933
• 12.19.2025 - 8-K Current report
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - DEF 14A Other definitive proxy statements
• 11.21.2025 - PRE 14A Other preliminary proxy statements
• 11.14.2025 - 8-K Current report